Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study.

NCT04826406 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT04826406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04826406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study.
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 3, 2021
Completion date
August 30, 2023
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, immune checkpoint inhibitors